<DOC>
	<DOCNO>NCT02399410</DOCNO>
	<brief_summary>The Bev-IP trial design assess feasibility efficacy combine treatment consist perioperative combination chemotherapy vascular endothelial growth factor A inhibitor bevacizumab cytoreductive surgery intraperitoneal oxaliplatin .</brief_summary>
	<brief_title>Perioperative Chemotherapy With Bevacizumab Colorectal Carcinomatosis</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>biopsy proven adenocarcinoma colon rectum synchronous metachronous peritoneal carcinomatosis . absence systemic disease , exception small , superficial liver metastasis , require minor surgery . resectable disease staging , laparoscopic evaluation exploration cytoreductive surgery intraperitoneal chemotherapy . complete macroscopic cytoreduction time surgery ( CC0/1 ) good general health status ( Karnofsky index &gt; 70 % ) expect life expectancy 6 month malignancy disease study serum creatinine &lt; 1.5 mg/dl calculate GFR â‰¥ 60 mL/min/1.73 serum total bilirubin &lt; 1.5 mg/dl platelet count &gt; 100,000/ml hemoglobin &gt; 9g/dl neutrophil granulocyte &gt; 1,500/ml International Normalized Ration ( INR ) 2 &lt; 2 Absence alcohol and/or drug abuse No inclusion clinical trial interfere study protocol No concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol Absence heart failure ( NYHA 2 &gt; 2 ) significant coronary artery disease No pregnancy breast feed Adequate contraception fertile patient No write informed consent tumour presence obstruction evidence extraabdominal disease extensive liver metastasis peritoneal cancer index &gt; 25 active bacterial , viral fungal infection active gastroduodenal ulcer parenchymal liver disease ( stage cirrhosis ) uncontrolled diabetes mellitus severe obstructive restrictive respiratory insufficiency psychiatric pathology capable affect comprehension judgment faculty Known allergy oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>cytoreductive surgery</keyword>
	<keyword>hipec</keyword>
	<keyword>perioperative chemotherapy</keyword>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>colorectal surgery</keyword>
</DOC>